六味安神胶囊联合艾司西酞普兰治疗抑郁症临床疗效观察  

Clinical efficacy of Liuwei Anshen capsule combined with Escitalopram in the treatment of depression

作　　者：毛龙金 高志勤 丁松柏 管莉 曹志永 董佳 MAO Long-jin;GAO Zhi-qin;DING Song-bai;GUAN Li;CAO Zhi-yong;DONG Jia(Military Psychiatry,904th Joint Logistics Support Force Hospital Changzhou Medical Area,Changzhou 213003,China;Sleep Medicine,904th Joint Logistics Support Force Hospital Changzhou Medical Area,Changzhou 213003,China;Department of Military Outpatient,General Hospital of Northern Theater Command,Shenyang 110016,China)

机构地区：[1]联勤保障部队第九〇四医院常州医疗区军事精神科,江苏常州213003 [2]联勤保障部队第九〇四医院常州医疗区睡眠医学科,江苏常州213003 [3]北部战区总医院军人门诊,辽宁沈阳110016

出　　处：《临床军医杂志》2024年第10期1010-1013,共4页Clinical Journal of Medical Officers

基　　金：全军医药卫生科研基金课题(14MS015)。

摘　　要：目的探讨六味安神胶囊联合艾司西酞普兰治疗抑郁症的临床疗效。方法选取联勤保障部队904医院常州医疗区自2022年1月至2024年1月收治的150例抑郁症患者为研究对象。根据不同的治疗方案将患者分为A组(n=72)与B组(n=78)。A组患者采用艾司西酞普兰治疗,B组患者采用六味安神胶囊联合艾司西酞普兰治疗。记录并比较两组患者的临床疗效与不良反应发生率。比较两组患者治疗前后生活质量评价量表(SF-36)评分、贝克自杀意念量表(BSS)评分、神经递质[去甲肾上腺素(NE)、5-羟色胺(5-HT)、多巴胺(DA)]、炎症因子[白细胞介素(IL)-6、IL-22、IL-1β],以及Toll样受体4/Nod样受体蛋白3(TLR4/NLRP3)通路表达水平。结果B组患者治疗总有效率为89.74%(70/78),高于A组的59.72%(43/72),差异有统计学意义(P<0.05)。治疗后,两组患者SF-36评分均升高,BSS评分均降低,且B组SF-36评分高于A组,BSS评分低于A组,差异均有统计学意义(P<0.05)。治疗后,两组患者IL-6、IL-21、IL-1β均降低,NE、5-HT、DA均升高,且B组IL-6、IL-21、IL-1β均低于A组,NE、5-HT、DA均高于A组,差异均有统计学意义(P<0.05)。治疗后,两组患者TLR4 mRNA、NLRP3 mRNA均降低,且B组均低于A组,差异均有统计学意义(P<0.05)。A组、B组患者不良反应发生率分别为2.78%(2/72)、3.85%(3/78),差异无统计学意义(P>0.05)。结论六味安神胶囊联合艾司西酞普兰治疗抑郁症疗效显著,可改善患者症状、炎症因子及神经递质水平,IL-6、IL-21、IL-1β等促炎因子表达下调可能与抑制TLR4/NLRP3通路表达有关。Objective To investigate the clinical efficacy of Liuwei Anshen capsule combined with Escitalopram in the treatment of depression.Methods A totoal of 150 patients with depression who were treated in 904th Joint Logistics Support Force Hospital Changzhou Medical Area from January 2022 to January 2024 were selected as the study objects.Patients were divided into group A(n=72)and group B(n=78)according to different treatment regiments.Group A was treated with escitalopram,group B was treated with Liuwei Anshen capsule combined with Escitalopram.The clinical efficacy and incidence of adverse reactions were recorded and compared between the two groups.The score of short form 36 questionnaire(SF-36),beck scale for suicide ideation(BSS),neurotransmitter[norepinephrine(NE),5-hydroxy tryptamine(5-HT),dopamine dopamine(DA)],inflammatory factors[interleukin(IL)-6,IL-22,IL-1β]before and after treatment were compared between the two groups.And the expression level of toll-like receptor 4/NOD-like receptor 3(TLR4/NLRP3)pathway.Results The total effective rate of group B was 89.74%(70/78),which was higher than 59.72%(43/72)of group A,and the difference was statistically significant(P<0.05).After treatment,SF-36 score increased and BSS score decreased in both groups,and SF-36 score in group B was higher than that in group A,and BSS score was lower than that in group A,with statistical significance(P<0.05).After treatment,IL-6,IL-21 and IL-1βin 2 groups were decreased,while NE,5-HT and DA were increased,and IL-6,IL-21 and IL-1βin group B were lower than those in group A,while NE,5-HT and DA were higher than those in group A,with statistical significance(P<0.05).After treatment,TLR4 mRNA and NLRP3 mRNA were decreased in 2 groups,and group B was lower than group A,the differences were statistically significant(P<0.05).The incidence of adverse reactions in group A and group B was 2.78%(2/72)and 3.85%(3/78),respectively,with no statistical significance(P>0.05).Conclusion Liuwei Anshen capsule combined with Escitalopram is effectiv

关 键 词：六味安神胶囊 Toll样受体4/Nod样受体蛋白3通路 抑郁症 艾司西酞普兰 

分 类 号：R749.4[医药卫生—神经病学与精神病学]